Vaxxinity, Inc. (VAXX)
| Previous Close | 0.0010 |
| Open | 0.0001 |
| Bid | 0.3550 x 0 |
| Ask | 0.4000 x 0 |
| Day's Range | 0.0001 - 0.0001 |
| 52 Week Range | 0.0001 - 1.3100 |
| Volume | |
| Avg. Volume | 13,223 |
| Market Cap | 12,678 |
| Beta (5Y Monthly) | 2.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4500 |
| Earnings Date | Nov 06, 2024 - Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
GlobeNewswireVaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological alpha-synuclein. CAPE CANAVERAL, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (OTC: VAXX), a U.S. company pioneering the development of a new class of medicines known as AIMs (active immunotherapy med
GlobeNewswireVaxxinity Issues Shareholder Letter
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu. To Shareholders of Vaxxinity, Inc.: Earlier today, we announced that we are delisting and deregistering our shares. A few weeks from now, we will no longe
